Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy.
BACKGROUND
The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.


METHODS
In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.


RESULTS
Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six- and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.


CONCLUSIONS
Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.
Department of Urology, Masshad University of Medical Sciences, Iran.
Mohammadali Mohammadzadeh
MM
Rezaei
Department of Urology, Masshad University of Medical Sciences, Iran.
Mohammadhadi Mohammadzadeh
MM
Rezaei
Department of Urology, Masshad University of Medical Sciences, Iran.
Alireza
A
Ghoreifi
Department of Urology, Masshad University of Medical Sciences, Iran.
Behzad Feyzzadeh
BF
Kerigh
Eur Urol. 2008 Oct;54(4):816-23
18243498
J Clin Endocrinol Metab. 2005 Feb;90(2):657-60
15562007
Clin Sci (Lond). 2003 Feb;104(2):195-201
12546642
J Clin Endocrinol Metab. 2001 Sep;86(9):4261-7
11549659
J Urol. 1995 Jul;154(1):100-4
7539852
Rev Urol. 2007;9 Suppl 1:S3-8
17387371
J Clin Oncol. 2006 Aug 20;24(24):3979-83
16921050
Eur Urol. 2010 Jan;57(1):49-59
19683858
Ther Adv Med Oncol. 2010 Mar 1;2(2):107-123
20543967
Asian J Androl. 2011 Nov;13(6):833-7
21785444
J Clin Oncol. 2011 Sep 10;29(26):3510-6
21844498
Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86
12072048
Gend Med. 2009;6 Suppl 1:60-75
19318219
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
17925537
J Oncol. 2015;2015:820403
26300918
Prostate Int. 2015 Sep;3(3):99-102
26473152
Aging Male. 2015;18(3):180-5
26004988
Cancer. 2006 Feb 1;106(3):581-8
16388523
Urology. 2007 Dec;70(6):1104-8
18158027
Prostate Int. 2013;1(1):23-30
24223398
Rev Urol. 2012;14(1-2):1-12
23172994
J Clin Oncol. 2009 Jul 20;27(21):3452-8
19506162
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46
19996060
J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):567-72
7626511
Cancer. 2005 Apr 15;103(8):1615-24
15742331
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
21685461
PLoS One. 2015 Mar 20;10(3):e0117344
25794005
J Clin Oncol. 2006 Sep 20;24(27):4448-56
16983113
Cancer. 2008 May 15;112(10):2188-94
18348297
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):742-50
20630664
Prostate Cancer Prostatic Dis. 2012 Sep;15(3):296-302
22733160